221 related articles for article (PubMed ID: 23775421)
1. Intratumoral temozolomide synergizes with immunotherapy in a T cell-dependent fashion.
Fritzell S; Sandén E; Eberstål S; Visse E; Darabi A; Siesjö P
Cancer Immunol Immunother; 2013 Sep; 62(9):1463-74. PubMed ID: 23775421
[TBL] [Abstract][Full Text] [Related]
2. Convection-enhanced delivery of temozolomide and whole cell tumor immunizations in GL261 and KR158 experimental mouse gliomas.
Enríquez Pérez J; Kopecky J; Visse E; Darabi A; Siesjö P
BMC Cancer; 2020 Jan; 20(1):7. PubMed ID: 31900109
[TBL] [Abstract][Full Text] [Related]
3. Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model.
Banissi C; Ghiringhelli F; Chen L; Carpentier AF
Cancer Immunol Immunother; 2009 Oct; 58(10):1627-34. PubMed ID: 19221744
[TBL] [Abstract][Full Text] [Related]
4. Local delivery of slow-releasing temozolomide microspheres inhibits intracranial xenograft glioma growth.
Dong J; Zhou G; Tang D; Chen Y; Cui B; Dai X; Zhang J; Lan Q; Huang Q
J Cancer Res Clin Oncol; 2012 Dec; 138(12):2079-84. PubMed ID: 22825126
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral COX-2 inhibition enhances GM-CSF immunotherapy against established mouse GL261 brain tumors.
Eberstål S; Sandén E; Fritzell S; Darabi A; Visse E; Siesjö P
Int J Cancer; 2014 Jun; 134(11):2748-53. PubMed ID: 24243648
[TBL] [Abstract][Full Text] [Related]
6. Microdialysis measurement of intratumoral temozolomide concentration after cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, in a U87 glioma model.
Grossman R; Tyler B; Rudek MA; Kim E; Zadnik P; Khan U; Blakeley JO; Pathak AP; Brem H
Cancer Chemother Pharmacol; 2013 Jul; 72(1):93-100. PubMed ID: 23649683
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effect of fibrin glue containing temozolomide against malignant glioma.
Anai S; Hide T; Takezaki T; Kuroda J; Shinojima N; Makino K; Nakamura H; Yano S; Kuratsu J
Cancer Sci; 2014 May; 105(5):583-91. PubMed ID: 24673719
[TBL] [Abstract][Full Text] [Related]
8. Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model.
Hanihara M; Kawataki T; Oh-Oka K; Mitsuka K; Nakao A; Kinouchi H
J Neurosurg; 2016 Jun; 124(6):1594-601. PubMed ID: 26636389
[TBL] [Abstract][Full Text] [Related]
9. Temozolomide combined with PD-1 Antibody therapy for mouse orthotopic glioma model.
Dai B; Qi N; Li J; Zhang G
Biochem Biophys Res Commun; 2018 Jul; 501(4):871-876. PubMed ID: 29758196
[TBL] [Abstract][Full Text] [Related]
10. Systemic Intravenous Adoptive Transfer of Autologous Lymphokine-activated αβ T-Cells Improves Temozolomide-induced Lymphopenia in Patients with Glioma.
Kanemura Y; Sumida M; Okita Y; Yoshioka E; Yamamoto A; Kanematsu D; Handa Y; Fukusumi H; Inazawa Y; Takada AI; Nonaka M; Nakajima S; Mori K; Goto S; Kamigaki T; Shofuda T; Moriuchi S; Yamasaki M
Anticancer Res; 2017 Jul; 37(7):3921-3932. PubMed ID: 28668896
[TBL] [Abstract][Full Text] [Related]
11. Aspirin-/TMZ-coloaded microspheres exert synergistic antiglioma efficacy via inhibition of β-catenin transactivation.
Shi ZD; Qian XM; Liu CY; Han L; Zhang KL; Chen LY; Zhang JX; Pu PY; Yuan XB; Kang CS;
CNS Neurosci Ther; 2013 Feb; 19(2):98-108. PubMed ID: 23230963
[TBL] [Abstract][Full Text] [Related]
12. [Establishment of a mouse model bearing orthotopic temozolomide-resistant glioma].
Shi L; Li H; Gu J; Song C; Li J; Chen L; Zhou Q; Qi S; Lu Y
Nan Fang Yi Ke Da Xue Xue Bao; 2021 Jan; 41(1):69-74. PubMed ID: 33509755
[TBL] [Abstract][Full Text] [Related]
13. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
14. Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model.
Kim TG; Kim CH; Park JS; Park SD; Kim CK; Chung DS; Hong YK
Clin Vaccine Immunol; 2010 Jan; 17(1):143-53. PubMed ID: 19889936
[TBL] [Abstract][Full Text] [Related]
15. Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy.
Zhu X; Fujita M; Snyder LA; Okada H
J Neurooncol; 2011 Aug; 104(1):83-92. PubMed ID: 21116835
[TBL] [Abstract][Full Text] [Related]
16. Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma.
de Gast GC; Batchelor D; Kersten MJ; Vyth-Dreese FA; Sein J; van de Kasteele WF; Nooijen WJ; Nieweg OE; de Waal MA; Boogerd W
Br J Cancer; 2003 Jan; 88(2):175-80. PubMed ID: 12610499
[TBL] [Abstract][Full Text] [Related]
17. Temozolomide does not impair gene therapy-mediated antitumor immunity in syngeneic brain tumor models.
Candolfi M; Yagiz K; Wibowo M; Ahlzadeh GE; Puntel M; Ghiasi H; Kamran N; Paran C; Lowenstein PR; Castro MG
Clin Cancer Res; 2014 Mar; 20(6):1555-1565. PubMed ID: 24501391
[TBL] [Abstract][Full Text] [Related]
18. Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts.
Carlson BL; Grogan PT; Mladek AC; Schroeder MA; Kitange GJ; Decker PA; Giannini C; Wu W; Ballman KA; James CD; Sarkaria JN
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):212-9. PubMed ID: 19695438
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of elongation factor-2 kinase augments the antitumor activity of Temozolomide against glioma.
Liu XY; Zhang L; Wu J; Zhou L; Ren YJ; Yang WQ; Ming ZJ; Chen B; Wang J; Zhang Y; Yang JM
PLoS One; 2013; 8(11):e81345. PubMed ID: 24303044
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II trial of combination of temozolomide chemotherapy and immunotherapy with fusions of dendritic and glioma cells in patients with glioblastoma.
Akasaki Y; Kikuchi T; Homma S; Koido S; Ohkusa T; Tasaki T; Hayashi K; Komita H; Watanabe N; Suzuki Y; Yamamoto Y; Mori R; Arai T; Tanaka T; Joki T; Yanagisawa T; Murayama Y
Cancer Immunol Immunother; 2016 Dec; 65(12):1499-1509. PubMed ID: 27688162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
